vs
BYLINE BANCORP, INC.（BY）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
BYLINE BANCORP, INC.的季度营收约是RIGEL PHARMACEUTICALS INC的1.6倍（$112.4M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 33.4%，领先350.6%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs 9.0%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 6.4%）
Byline Bank是总部位于美国伊利诺伊州芝加哥的银行，为银行控股公司Byline Bancorp, Inc.的核心子公司，同时是全美SBA 7(a)贷款项目的第四大放贷机构，为客户提供专业的银行及融资相关服务。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
BY vs RIGL — 直观对比
营收规模更大
BY
是对方的1.6倍
$69.8M
营收增速更快
RIGL
高出12.1%
9.0%
净利率更高
RIGL
高出350.6%
33.4%
两年增速更快
RIGL
近两年复合增速
6.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $112.4M | $69.8M |
| 净利润 | $37.6M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | — | 33.2% |
| 净利率 | 33.4% | 384.0% |
| 营收同比 | 9.0% | 21.2% |
| 净利润同比 | 33.0% | 1769.2% |
| 每股收益（稀释后） | $0.83 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BYRIGL
| Q1 26 | $112.4M | — | ||
| Q4 25 | $117.0M | $69.8M | ||
| Q3 25 | $115.7M | $69.5M | ||
| Q2 25 | $110.5M | $101.7M | ||
| Q1 25 | $103.1M | $53.3M | ||
| Q4 24 | $104.7M | $57.6M | ||
| Q3 24 | $101.8M | $55.3M | ||
| Q2 24 | $99.4M | $36.8M |
净利润BYRIGL
| Q1 26 | $37.6M | — | ||
| Q4 25 | $34.5M | $268.1M | ||
| Q3 25 | $37.2M | $27.9M | ||
| Q2 25 | $30.1M | $59.6M | ||
| Q1 25 | $28.2M | $11.4M | ||
| Q4 24 | $30.3M | $14.3M | ||
| Q3 24 | $30.3M | $12.4M | ||
| Q2 24 | $29.7M | $-1.0M |
毛利率BYRIGL
| Q1 26 | — | — | ||
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% |
营业利润率BYRIGL
| Q1 26 | — | — | ||
| Q4 25 | 40.1% | 33.2% | ||
| Q3 25 | 43.1% | 40.9% | ||
| Q2 25 | 35.2% | 60.1% | ||
| Q1 25 | 36.4% | 23.9% | ||
| Q4 24 | 38.6% | 28.9% | ||
| Q3 24 | 39.3% | 25.4% | ||
| Q2 24 | 40.4% | 1.2% |
净利率BYRIGL
| Q1 26 | 33.4% | — | ||
| Q4 25 | 34.1% | 384.0% | ||
| Q3 25 | 32.1% | 40.2% | ||
| Q2 25 | 27.2% | 58.6% | ||
| Q1 25 | 27.4% | 21.5% | ||
| Q4 24 | 34.3% | 24.9% | ||
| Q3 24 | 29.8% | 22.5% | ||
| Q2 24 | 29.9% | -2.8% |
每股收益（稀释后）BYRIGL
| Q1 26 | $0.83 | — | ||
| Q4 25 | $0.77 | $14.11 | ||
| Q3 25 | $0.82 | $1.46 | ||
| Q2 25 | $0.66 | $3.28 | ||
| Q1 25 | $0.64 | $0.63 | ||
| Q4 24 | $0.68 | $0.82 | ||
| Q3 24 | $0.69 | $0.70 | ||
| Q2 24 | $0.68 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $198.4M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $1.3B | $391.5M |
| 总资产 | $9.9B | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资BYRIGL
| Q1 26 | $198.4M | — | ||
| Q4 25 | $149.1M | $155.0M | ||
| Q3 25 | $259.0M | $137.1M | ||
| Q2 25 | $218.3M | $108.4M | ||
| Q1 25 | $421.3M | $77.1M | ||
| Q4 24 | $563.1M | $77.3M | ||
| Q3 24 | $452.6M | $61.1M | ||
| Q2 24 | $730.5M | $49.1M |
总债务BYRIGL
| Q1 26 | — | — | ||
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M |
股东权益BYRIGL
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $391.5M | ||
| Q3 25 | $1.2B | $117.6M | ||
| Q2 25 | $1.2B | $81.9M | ||
| Q1 25 | $1.1B | $18.6M | ||
| Q4 24 | $1.1B | $3.3M | ||
| Q3 24 | $1.1B | $-14.6M | ||
| Q2 24 | $1.0B | $-29.9M |
总资产BYRIGL
| Q1 26 | $9.9B | — | ||
| Q4 25 | $9.7B | $513.6M | ||
| Q3 25 | $9.8B | $242.5M | ||
| Q2 25 | $9.7B | $206.7M | ||
| Q1 25 | $9.6B | $176.0M | ||
| Q4 24 | $9.5B | $164.0M | ||
| Q3 24 | $9.4B | $139.4M | ||
| Q2 24 | $9.6B | $128.4M |
负债/权益比BYRIGL
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BYRIGL
| Q1 26 | — | — | ||
| Q4 25 | $140.3M | $22.0M | ||
| Q3 25 | $38.3M | $24.0M | ||
| Q2 25 | $16.3M | $30.5M | ||
| Q1 25 | $27.1M | $-893.0K | ||
| Q4 24 | $175.2M | $14.5M | ||
| Q3 24 | $19.8M | $21.7M | ||
| Q2 24 | $40.1M | $302.0K |
自由现金流BYRIGL
| Q1 26 | — | — | ||
| Q4 25 | $136.3M | — | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $15.2M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $171.2M | — | ||
| Q3 24 | $19.1M | — | ||
| Q2 24 | $39.4M | — |
自由现金流率BYRIGL
| Q1 26 | — | — | ||
| Q4 25 | 116.5% | — | ||
| Q3 25 | 32.8% | — | ||
| Q2 25 | 13.7% | — | ||
| Q1 25 | 24.3% | — | ||
| Q4 24 | 163.5% | — | ||
| Q3 24 | 18.8% | — | ||
| Q2 24 | 39.7% | — |
资本支出强度BYRIGL
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 2.0% | — | ||
| Q4 24 | 3.8% | — | ||
| Q3 24 | 0.6% | — | ||
| Q2 24 | 0.7% | — |
现金转化率BYRIGL
| Q1 26 | — | — | ||
| Q4 25 | 4.06× | 0.08× | ||
| Q3 25 | 1.03× | 0.86× | ||
| Q2 25 | 0.54× | 0.51× | ||
| Q1 25 | 0.96× | -0.08× | ||
| Q4 24 | 5.78× | 1.01× | ||
| Q3 24 | 0.65× | 1.75× | ||
| Q2 24 | 1.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
